TOP TEN perturbations for 38978_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38978_at
Selected probe(set): 209063_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38978_at (209063_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-3.112033Number of Samples:3 / 3
Experimental | oncolytic herpes simplex virus study 2 |
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample
Relative Expression (log2-ratio):2.0976439Number of Samples:2 / 2
Experimental | conditioned medium study 1 (HS5) |
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h. | |
Control | untreated monocyte (CD14+) sample |
Untreated CD14+ monocytes from two different donors. |
conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample
Relative Expression (log2-ratio):2.0723543Number of Samples:2 / 2
Experimental | conditioned medium study 1 (HS27a) |
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h. | |
Control | untreated monocyte (CD14+) sample |
Untreated CD14+ monocytes from two different donors. |
kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample
Relative Expression (log2-ratio):-2.026082Number of Samples:2 / 5
Experimental | kidney transplantation study 15 (8 week) |
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
Control | normal monocyte (CD14+) sample |
CD14+ monocyte samples derived from healthy control subjects. |
endometriosis study 6 (minimal/mild endo.; pro. MCP) / normal endometrium tissue (pro. MCP)
Relative Expression (log2-ratio):-1.8572998Number of Samples:12 / 20
Experimental | endometriosis study 6 (minimal/mild endo.; pro. MCP) |
Endometrial tissue samples from women with minimal or mild endometriosis and pelvic pain and/or infertility collected in the proliferative menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
Control | normal endometrium tissue (pro. MCP) |
Normal endometrial tissue samples from women collected in the proliferative menstrual cycle phase (MCP). The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. |
F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-1.7830677Number of Samples:4 / 6
Experimental | F. tularensis study 1 (tularensis Schu S4) |
Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours. | |
Control | uninfected peripheral blood monocyte sample |
Peripheral blood monocytes uninfected. |
F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-1.5406218Number of Samples:4 / 6
Experimental | F. tularensis study 1 (novicida) |
Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours. | |
Control | uninfected peripheral blood monocyte sample |
Peripheral blood monocytes uninfected. |
colorectal cancer study 25 / adjacent colon tissue
Relative Expression (log2-ratio):1.5187807Number of Samples:94 / 17
Experimental | colorectal cancer study 25 |
Human primary colorectal carcinoma sample. | |
Control | adjacent colon tissue |
Normal colon tissue samples adjacent to tumor from patients with colorectal cancer. |
bone cancer study 1 (PDX; osteosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):1.5172033Number of Samples:2 / 2
Experimental | bone cancer study 1 (PDX; osteosarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted). | |
Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |
atopic dermatitis study 21 (lesional; dermis) / normal dermis tissue
Relative Expression (log2-ratio):-1.43717Number of Samples:5 / 6
Experimental | atopic dermatitis study 21 (lesional; dermis) |
Lesional dermal samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
Control | normal dermis tissue |
Dermal samples isolated from healthy subjects by laser capture microdissection. |
Organism: Homo sapiens
Gene: 38978_at
Selected probe(set): 209063_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38978_at (209063_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-3.112033Number of Samples:3 / 3
Experimental | oncolytic herpes simplex virus study 2 |
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample
Relative Expression (log2-ratio):2.0976439Number of Samples:2 / 2
Experimental | conditioned medium study 1 (HS5) |
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h. | |
Control | untreated monocyte (CD14+) sample |
Untreated CD14+ monocytes from two different donors. |
conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample
Relative Expression (log2-ratio):2.0723543Number of Samples:2 / 2
Experimental | conditioned medium study 1 (HS27a) |
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h. | |
Control | untreated monocyte (CD14+) sample |
Untreated CD14+ monocytes from two different donors. |
kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample
Relative Expression (log2-ratio):-2.026082Number of Samples:2 / 5
Experimental | kidney transplantation study 15 (8 week) |
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
Control | normal monocyte (CD14+) sample |
CD14+ monocyte samples derived from healthy control subjects. |
endometriosis study 6 (minimal/mild endo.; pro. MCP) / normal endometrium tissue (pro. MCP)
Relative Expression (log2-ratio):-1.8572998Number of Samples:12 / 20
Experimental | endometriosis study 6 (minimal/mild endo.; pro. MCP) |
Endometrial tissue samples from women with minimal or mild endometriosis and pelvic pain and/or infertility collected in the proliferative menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
Control | normal endometrium tissue (pro. MCP) |
Normal endometrial tissue samples from women collected in the proliferative menstrual cycle phase (MCP). The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. |
F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-1.7830677Number of Samples:4 / 6
Experimental | F. tularensis study 1 (tularensis Schu S4) |
Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours. | |
Control | uninfected peripheral blood monocyte sample |
Peripheral blood monocytes uninfected. |
F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-1.5406218Number of Samples:4 / 6
Experimental | F. tularensis study 1 (novicida) |
Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours. | |
Control | uninfected peripheral blood monocyte sample |
Peripheral blood monocytes uninfected. |
colorectal cancer study 25 / adjacent colon tissue
Relative Expression (log2-ratio):1.5187807Number of Samples:94 / 17
Experimental | colorectal cancer study 25 |
Human primary colorectal carcinoma sample. | |
Control | adjacent colon tissue |
Normal colon tissue samples adjacent to tumor from patients with colorectal cancer. |
bone cancer study 1 (PDX; osteosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):1.5172033Number of Samples:2 / 2
Experimental | bone cancer study 1 (PDX; osteosarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted). | |
Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |
atopic dermatitis study 21 (lesional; dermis) / normal dermis tissue
Relative Expression (log2-ratio):-1.43717Number of Samples:5 / 6
Experimental | atopic dermatitis study 21 (lesional; dermis) |
Lesional dermal samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
Control | normal dermis tissue |
Dermal samples isolated from healthy subjects by laser capture microdissection. |